Global pharmaceutical powerhouse, Lupin Limited has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Nagpur Unit-1 manufacturing facility, specializing in oral solid dosage forms. This significant milestone follows the facility’s latest inspection in July 2023, with the U.S. FDA granting it a Voluntary Action Indicated (VAI) classification.

Nilesh Gupta, Managing Director of Lupin, expressed delight, stating, “We are pleased to receive the EIR with a VAI status from the U.S. FDA for the recent inspection of our Nagpur Unit-1 facility. This achievement underscores our commitment to quality and compliance and also mirrors our core values, reaffirming our commitment to providing high-quality healthcare solutions to our patients around the world.”

  Lupin, Nagpur, Nilesh Gupta, US FDA